• FirefoxInstall the new Firefox »
  •  Dow Down0.47% Nasdaq Down0.56%

    StemCells Inc. (STEM)

    1.38 Up 0.27(24.32%) Mar 3, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    StemCells Inc.
    7707 Gateway Boulevard
    Suite 140
    Newark, CA 94560
    United States - Map
    Phone: 510-456-4000
    Fax: 510-456-4001
    Website: http://www.stemcellsinc.com

    Index Membership:N/A
    Full Time Employees:58

    Business Summary 

    StemCells, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of stem cell therapeutics, and related tools and technologies for stem cell-based research and drug discovery and development. It develops HuCNS-SC cells that completed Phase I clinical trial in pelizaeus-merzbacher disease, a fatal myelination disorder in brain; completed a Phase I clinical trial in infantile and late infantile neuronal ceroid lipofuscinosis, which is a neurodegenerative disorder of the brain; and conducting preclinical studies in alzheimer’s disease. The company is also developing HuCNS-SC cells that are in Phase I/II clinical trial for the treatment of chronic spinal cord injury, as well as for dry age-related macular degeneration. In addition, it is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company markets a range of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. Its proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. The company serves researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on StemCells Inc.

    Key Executives 
    Mr. Martin M. McGlynn , 69
    Chief Exec. Officer, Pres, Director, Member of Strategic Transactions Committee, Chief Exec. Officer of StemCells California Inc and Pres of StemCells California Inc
    Dr. Ann Tsukamoto Ph.D., 62
    Exec. VP of Scientific & Strategic Alliances
    Mr. Gregory T. Schiffman MBA, CPA, 58
    Chief Financial Officer and Exec. VP of Fin.
    Mr. George Koshy ,
    Chief Accounting Officer and Controller
    Ms. Megan Meloni ,
    Director of Investor Relations & Corp. Communications
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders